Compare Global X Copper Miners ETF (COPX) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Copper Miners ETF vs Illumina, Inc. — how do they compare? Global X Copper Miners ETF trades at $83.59 (market cap $7.37B), while Illumina, Inc. trades at $265 (market cap $40.43B). The key difference: Illumina, Inc. is far larger — about 5.5× Global X Copper Miners ETF's market cap, and Illumina, Inc. is trading nearer its 52-week high, Global X Copper Miners ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Global X Copper Miners ETF for 50 Days and Illumina, Inc. for 83 Days on average.
| COPX | ILMN | |
|---|---|---|
Market Cap | $7.37B | $40.43B |
Volume | 1,988,532 | 2,948,626 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $96.45 | $293.69 |
52-Week Low | $57.43 | $91.00 |
Typical Hold Time | 50 Days | 83 Days |
Enterprise Value | — | $41.79B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
COPX (Global X Copper Miners ETF) is trading at $83.58, down 3.13% with a bearish technical signal. The ETF faces selling pressure with 15 sell signals versus 2 buy signals across technical indicators. Copper fundamentals remain strong with prices near all-time highs above $6.85 per pound, driven by AI infrastructure demand and supply constraints. Recent news highlights copper's critical role in electrification and AI infrastructure, though technical indicators suggest near-term weakness.
The long-term copper thesis remains compelling due to structural supply deficits and AI-driven demand growth. However, near-term risks include potential Federal Reserve policy impacts and mining equity underperformance relative to copper prices. The ETF offers operational leverage to copper prices but faces volatility from global surplus projections and macroeconomic factors.
Illumina (ILMN) trades at $264.40, down 3.34% on the day but up significantly year-to-date with strong technical momentum. The stock shows bullish moving average signals and trades near pivot point resistance at $268. Fundamentally, the company has delivered three consecutive quarterly earnings beats and returned to profitability in 2025 with $850 million net income after previous losses. Recent catalysts include S&P 500 inclusion effective September 21, 2026, and growing AI integration in genomics applications.
The outlook remains positive with analyst consensus favoring Buy ratings (54%) and a $241 price target, though current price exceeds consensus. Key opportunities include sequencing growth and AI-driven biological data expansion, while risks involve China market headwinds and elevated valuation multiples. Earnings growth and S&P 500 inclusion provide near-term catalysts, but the stock trades at premium valuations with P/E of 49.96 requiring sustained execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X Copper Miners ETF
COPX tracks the Solactive Global Copper Miners Total Return Index, providing broad exposure to companies worldwide involved in copper mining, refining, and exploration. It serves as an equity-based alternative to copper futures, offering a leveraged play on copper demand driven by global infrastructure and the clean energy transition.
Read more on COPX →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
